Other languages Spago Nanomedical AB

Equities

SPAGO

SE0004899474

Market Closed - Nasdaq Stockholm Other stock markets 12:00:00 2024-07-03 pm EDT			5-day change	1st Jan Change
0.292 ^SEK	+2.82%		-10.98%	-10.70%

May. 20	Spago Nanomedical Provides an Update on Tumorad-01, Trial Proceeds as Planned	CI
May. 02	Spago Nanomedical AB Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Other languages

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Spago Nanomedical Provides an Update on Tumorad-01, Trial Proceeds as Planned	May. 20
Spago Nanomedical AB Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 02
Spago Nanomedical AB Reports Favorable Data in Breast Cancer Model with Tumorad	Apr. 24
Spago Nanomedical AB Announces Appointment of Birgitta Rembratt Svensson as Head of CMC & Supply, Effective June 1, 2024	Apr. 16
Spago Nanomedical AB Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 07
Spago Nanomedical AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 07
Spago Nanomedical Proceeds to the Next Dose Level in the Phase I/IIa Study Tumorad-01	Jan. 10
Spago Nanomedical Announces Positive Top Line Data from a Clinical Phase IIa Study in Patients with Endometriosis	Dec. 20
Spago Nanomedical Reports Positive Top Line Data from Clinical Phase IIa Study SPAGOPIX-02 in Patients with Endometriosis	Dec. 15
Spago Nanomedical AB Announces First Patient Dosed in Spago Nanomedical's Clinical Phase I/IIA Study Within the Tumorad(R) Program	Dec. 07
Spago Nanomedical AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 03
Spago Nanomedical AB Announces Publication of Four New Patent Applications Filed with the European Patent Office	23-10-24
Spago Nanomedical Announces Cancer Therapy Approved for Phase I/IIa	23-10-23
Spago Nanomedical AB Receives Approval to Initiate the Clinical Phase I/IIa Study with Tumorad in Australia	23-10-19
Spago Nanomedical AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-07-31
Spago Nanomedical Updates on the Clinical Phase IIa Study SPAGOPIX-02	23-06-28
Spago Nanomedical AB Announces Establishment of A Scientific Advisory Board	23-06-13
Spago Nanomedical AB Submits Application to Start Tumorad(R) Clinical Phase I/IIa Study	23-05-23
Spago Nanomedical AB Elects New Directors	23-05-10
Spago Nanomedical AB Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-09

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Spago Nanomedical AB

Equities

SPAGO

SE0004899474

Other languages

Filters